ARTICLE | Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

December 7, 2009 8:00 AM UTC

Ohr updated its pipeline, which includes compounds from Advanced Viral and Genaera Corp. Ohr acquired AVR118 and AVR123 from Advanced Viral in March for $100,000 in cash, plus a $500,000 convertible debenture secured by the compounds. AVR118, a peptide nucleic acid-type immunomodulator in Phase II testing to treat cachexia in cancer patients was renamed OHR118. AVR123, a topical formulation of OHR118 in Phase I testing for wound healing, was renamed OHR123. Advanced Viral ceased operations in February due to insufficient funding (see BioCentury, Feb. 2). ...